KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $3.8 billion.

  • Biomarin Pharmaceutical's Non-Current Assets fell 90.34% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 billion, marking a year-over-year decrease of 343.62%. This contributed to the annual value of $3.8 billion for FY2024, which is 332.01% down from last year.
  • Biomarin Pharmaceutical's Non-Current Assets amounted to $3.8 billion in Q3 2025, which was down 90.34% from $3.7 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Non-Current Assets peaked at $3.9 billion during Q1 2024, and registered a low of $3.5 billion during Q1 2021.
  • Its 5-year average for Non-Current Assets is $3.7 billion, with a median of $3.7 billion in 2022.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Non-Current Assets surged by 3489.98% in 2021 and then plummeted by 536.46% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Non-Current Assets stood at $3.7 billion in 2021, then decreased by 2.86% to $3.6 billion in 2022, then grew by 7.23% to $3.9 billion in 2023, then decreased by 3.32% to $3.8 billion in 2024, then rose by 0.1% to $3.8 billion in 2025.
  • Its Non-Current Assets was $3.8 billion in Q3 2025, compared to $3.7 billion in Q2 2025 and $3.7 billion in Q1 2025.